Polymorphisms in plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes
Parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine
Abstract
Adequate clinical and parasitologic cure artemisinin combination therapies relies on the artemisinin component and the partner drug. Some resistance genes have been found to be associated with decreased sensitivity to amodiaquine and lumefantrine, but effects on therapeutic responses to artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) have not been clearly defined.
Individual patient data from 31 clinical trials were harmonized and pooled using standardized methods from the WorldWide Antimalarial Resistance Network. Monitoring selection and responding to emerging signs of drug resistance are critical tools for preserving efficacy of artemisinin combination therapies; determination of the prevalence of at least pfcrt K76T and pfmdr1 N86Y should now be routine.
Citation
Venkatesan M et al. Polymorphisms in plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: Parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. (2014) The American Journal of Tropical Medicine and Hygiene Volume 91, Issue 4 doi:10.4269/ajtmh.14-0031.